secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001193125-25-037619
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra sells PRV for $150M cash; funds MIPLYFFA & OLPRUVA launches
-----------------------------------------------------------------

- Gross proceeds of $150M, payable in cash at closing; expected within 30-45 days.
- PRV granted in Sep 2024 upon FDA approval of MIPLYFFA for Niemann-Pick type C.
- Transaction subject to HSR waiting period expiration; Cantor Fitzgerald advised.
- CFO states non-dilutive capital strengthens balance sheet, supports commercial launches and pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000119312525037619/0001193125-25-037619-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000119312525037619/d928575d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-037619

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer